Cassady Schiller Wealth Management LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Cassady Schiller Wealth Management LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 1.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 8,154 shares of the company’s stock after purchasing an additional 128 shares during the period. Cassady Schiller Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,179,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the third quarter worth about $35,000. Activest Wealth Management bought a new position in shares of Johnson & Johnson during the third quarter worth about $40,000. Finally, NewSquare Capital LLC lifted its position in shares of Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after purchasing an additional 172 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $162.94 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market cap of $392.29 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. The stock’s 50 day moving average price is $154.98 and its 200 day moving average price is $156.27. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Barclays raised their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.